ArticleEuropean journal of rheumatology2025
Bromocriptine in Rheumatic Diseases: A Review.
Article in European journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperprolactinemia is frequent in rheumatic diseases. Bromocriptine (BRC) is an antagonist of pro- lactin and was studied in a few rheumatic diseases with controversial results. The aim of the present study was to review articles on BRC in rheumatic diseases. Articles on lupus, rheumatoid arthritis, pso- riatic arthritis (PsA), and reactive arthritis were found. Fourteen articles were found. In lupus, 5 articles evaluated BRC in a 2.5-7.5 mg/day dosage. The follow-up varied from 6 to 14 months. They showed improvement in lupus disease activity (Lupus Disease Activity Index or Lupus activity measure scores) in 4/5; a trend was verified in another article, 1/5, and one study evaluated improvement in the mood of the systemic lupus erythematosus patients. In RA, there are 4 articles with 119 patients. The BRC dosage ranged from 5 mg/day to 10 mg TID. About 2/4 of the articles showed improvements [morn- ing stiffness and Health Assessment Questionnaire (HAQ)], and 2/4 did not show any difference. Regarding PsA and reactive arthritis, 5 articles with 43 patients were found. The BRC dose varied from 2.5 to 30 mg/day. All studies showed improvements of the studied diseases. Side effects were mild and infrequent. In conclusion, BRC seems to be efficacious in a few rheumatic diseases (lupus, PsA, RA, and Reiter's), with mild side effects. Future studies with a larger number of participants and in other rheumatic diseases are needed.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.